Cargando…

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer

Detalles Bibliográficos
Autores principales:	Bertucci, François, De Nonneville, Alexandre, Finetti, Pascal, Mamessier, Emilie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397558/ https://www.ncbi.nlm.nih.gov/pubmed/37278484 http://dx.doi.org/10.1002/cac2.12447

Ejemplares similares

The MonarchE trial: improving the clinical outcome in HR(+)/HER2(−) early breast cancer: recent results and next steps
por: Bertucci, François, et al.
Publicado: (2023)

WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2021)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
por: Boudin, Laurys, et al.
Publicado: (2022)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Validation and comparison of the molecular classifications of pancreatic carcinomas
por: Birnbaum, David J., et al.
Publicado: (2017)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

The gene signature of tertiary lymphoid structures within ovarian cancer predicts the prognosis and immunotherapy benefit
por: Hou, Yue, et al.
Publicado: (2023)

PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
por: Birnbaum, David Jeremie, et al.
Publicado: (2023)

A machine learning-based algorithm to eliminate breast and axillary surgery in patients with breast cancer and pathological complete response after neoadjuvant chemotherapy
por: de Nonneville, Alexandre, et al.
Publicado: (2023)

The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy
por: Bertucci, François, et al.
Publicado: (2015)

The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
por: Bertucci, François, et al.
Publicado: (2018)

Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?
por: Aulas, Anaïs, et al.
Publicado: (2020)

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients
por: Lopresti, Alexia, et al.
Publicado: (2022)

Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy
por: Devi, Gayathri R., et al.
Publicado: (2021)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

Tertiary Lymphoid Structures as Mediators of Immunotherapy Response
por: Vaghjiani, Raj G., et al.
Publicado: (2022)

Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer
por: Zhou, Lin, et al.
Publicado: (2021)

Kinome expression profiling and prognosis of basal breast cancers
por: Sabatier, Renaud, et al.
Publicado: (2011)

Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients
por: Aulas, Anaïs, et al.
Publicado: (2022)

Prognostic and predictive value of PDL1 expression in breast cancer
por: Sabatier, Renaud, et al.
Publicado: (2014)

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
por: Goncalves, Anthony, et al.
Publicado: (2021)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma
por: Shang, Taiyu, et al.
Publicado: (2023)

Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy
por: Groenewold, M.D., et al.
Publicado: (2022)

Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
por: Monneur, Audrey, et al.
Publicado: (2017)

A 25-gene classifier predicts overall survival in resectable pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2017)

Tertiary Lymphoid Organs in Cancer Immunology: Mechanisms and the New Strategy for Immunotherapy
por: Lin, Liangbin, et al.
Publicado: (2019)

Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies
por: N, Jacquelot, et al.
Publicado: (2021)

Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies
por: Trüb, Marta, et al.
Publicado: (2021)

B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
por: Lauss, Martin, et al.
Publicado: (2022)

Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy
por: Zou, Xinlei, et al.
Publicado: (2023)

Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma
por: Kuwabara, Shota, et al.
Publicado: (2019)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8rheq4mjo2ebs7ka5p8jv3kj23